AVEO Pharmaceuticals, Inc. (AVEO)
| Market Cap | 238.83M |
| Revenue (ttm) | 5.90M |
| Net Income (ttm) | -28.54M |
| Shares Out | 25.81M |
| EPS (ttm) | -1.52 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 26 |
| Last Price | $8.21 |
| Previous Close | $8.29 |
| Change ($) | -0.08 |
| Change (%) | -0.97% |
| Day's Open | 8.25 |
| Day's Range | 8.06 - 8.39 |
| Day's Volume | 270,064 |
| 52-Week Range | 2.60 - 9.99 |
BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced that it has received a commitment letter for an incremental $10 million loan from Hercules Capital, Inc. (NYSE: HTGC, “Her...
BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced the presentation of results from the Phase 1b portion of the Phase 1b/2 DEDUCTIVE clinical trial of tivozanib (FOTIVDA®), ...
BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today highlighted its recent progress and outlined its 2021 outlook. “We remain keenly focused on building out our commercial team ahead o...
BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced that Michael Bailey, president and chief executive officer of AVEO, will participate in two upcoming virtual investor conf...
AVEO Oncology Announces Webcast of Presentation at the 39th Annual J.P. Morgan Healthcare Conference
BOSTON, Mass.--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced that Michael Bailey, president and chief executive officer of AVEO, will present at the 39th Annual J.P. Morgan Hea...
AVEO is preparing for the potential U.S. commercial launch for Tivozanib in R/R RCC. The FDA has set the PDUFA Date for March 31st, 2021.
BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced that Michael Bailey, president and chief executive officer of AVEO, will present at the Stifel 2020 Virtual Healthcare Con...
AVEO (AVEO) delivered earnings and revenue surprises of -37.50% and -5.39%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today reported financial results for the third quarter ended September 30, 2020 and provided a business update. “In advance of the Food an...
BOSTON & HEMEL HEMPSTEAD, England--(BUSINESS WIRE)--AVEO Oncology (NASDAQ: AVEO) and EUSA Pharma today announced that previously reported results from the Phase 1b/2 TiNivo study of oral (PO) ...
AVEO (AVEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
On AVEO Pharmaceuticals' (AVEO) third-quarter earnings call, investor focus will be on the updates related to its NDA that seeks an approval for tivozanib to treat RCC in the United States.
BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced the appointment of David Crist as Vice President of Sales. In this role, Mr. Crist will be responsible for building out AV...
AVEO Pharmaceuticals (AVEO) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.
BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced that final overall survival (OS) results from its Phase 3 TIVO-3 study were published in the journal European Urology. TIV...
As of late, it has definitely been a great time to be an investor AVEO Pharmaceuticals.
AVEO reclaims complete rights to ficlatuzumab from Biodesix for an undisclosed sum. The candidate is being developed for several cancer indications.
AVEO (AVEO) reported earnings 30 days ago. What's next for the stock?
AVEO Pharmaceuticals (AVEO) seeks an FDA nod for Fotivda in the United States to treat relapsed or refractory RCC. A decision from the regulatory agency is expected on Mar 31, 2021.
BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced that it has regained full global rights to ficlatuzumab, AVEO’s potent hepatocyte growth factor (HGF) inhibitory antibody ...
BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced that Michael Bailey, president and chief executive officer of AVEO, will participate in two upcoming virtual investor conf...
AVEO (AVEO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
AVEO (AVEO) reports a narrower-than-expected loss but misses sales estimates in the second quarter of 2020.
AVEO (AVEO) delivered earnings and revenue surprises of 17.65% and -49.22%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today reported financial results for the second quarter ended June 30, 2020 and provided a business update. “The first half of 2020 was on...
AVEO (AVEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced that it has earned a $2.8 million development milestone payment from partner Kyowa Kirin Co., Ltd. (Kyowa Kirin).
BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced the closing of its previously announced underwritten public offering of 9,725,000 shares of its common stock, which includ...
Aveo Oncology: Managing A Position Following Positive ASCO Data Readout
AVEO's new drug application submission for tivozanib as a treatment of relapsed or refractory renal cell carcinoma gets acceptance from the FDA. A decision is expected on Mar 31, 2021.
Investors need to pay close attention to AVEO Pharmaceuticals (AVEO) stock based on the movements in the options market lately.
AVEO (AVEO) reported earnings 30 days ago. What's next for the stock?
AVEO Pharmaceuticals (AVEO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
AVEO (AVEO) delivered earnings and revenue surprises of -4.00% and -65.16%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
AVEO (AVEO) reported earnings 30 days ago. What's next for the stock?
AVEO ceases the phase II CyFi-2 study on ficlatuzumab plus high-dose cytarabine for treating patients with relapsed/refractory acute myeloid leukemia to combat the COVID-19 outbreak.
Even though AVEO Pharmaceuticals (AVEO) reports narrower-than-estimated loss in the fourth quarter, its revenues miss the mark.
AVEO (AVEO) delivered earnings and revenue surprises of 51.72% and -63.62%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
AVEO (AVEO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AVEO (AVEO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
AVEO: Still A Speculative Buy Ahead Of FOTIVDA NDA Submission
AVEO releases results from a phase Ib study on ficlatuzumab in combination with nab-paclitaxel and gemcitabine for treating advanced pancreatic cancer. Shares inch up.
AVEO (AVEO) reported earnings 30 days ago. What's next for the stock?
AVEO Pharmaceuticals (AVEO) rides high on both earnings and revenue beat in the third quarter. Shares rise.
AVEO Oncology recently announced that the FDA has once again recommended the company hold off on submitting FOTIVDA's NDA for RCC. AVEO intends to file NDA in Q1 of 2020.
AVEO (AVEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AVEO Oncology has been struggling lately, but the selling pressure may be coming to an end soon.
AVEO (AVEO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
AVEO recently publicized the results of their interim analysis of FOTIVDA in advanced RCC. The company reported an improved OS HR ratio of 0.99.
AVEO posts positive updated results from the second prespecified overall survival analysis of Fotivda for treating highly refractory metastatic renal cell carcinoma. Stock up more than 30%.
About AVEO
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical needs. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC). The company has also completed a Phase III TIVO-3 trial of tivozanib for the treatment of RCC; and initiated enrollment in a phase Ib/II clinical trial of tivozanib in combination w... [Read more...]
| Industry Biotechnology | IPO Date Mar 12, 2010 |
| CEO Michael Bailey | Employees 19 |
| Stock Exchange NASDAQ | Ticker Symbol AVEO |
Analyst Forecasts
According to 4 analysts, the average rating for AVEO stock is "Strong Buy." The 12-month stock price forecast is 12.00, which is an increase of 46.16% from the latest price.